https://european-biotechnology.net/wp-content/uploads/2025/09/Servier_Fragile-X-Syndrome-1030x468-1.png
468
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-09-09 05:29:302025-09-09 05:29:30Servier acquires Kaerus Bioscience’s FXS candidate for US$450m
https://european-biotechnology.net/wp-content/uploads/2025/09/NRG_1650536385_REE9VqiEAxf9lNiEm5SSpvIR9FyVo8Ko-e1757312244435.jpg
480
960
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-09-08 07:00:342025-09-08 07:00:34NRG Therapeutics Ltd bags £50m in Series B financing
https://european-biotechnology.net/wp-content/uploads/2025/09/BIONTECH-HQ_393139602_Zb0h3vxEfpoM8LCZnO6asKBbaVrnKYhj-e1757228010811.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-09-07 06:54:452025-09-07 06:54:45BioNTech‘s breast cancer ADC outperforms Roche’s Kadcyla
https://european-biotechnology.net/wp-content/uploads/2025/09/Blackmint-Studio_1390096280_U26uHM9LFjqU55doX7W4iHtws8esSYLR.jpg
240
429
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-09-07 04:53:222025-09-07 04:53:22Alt protein: EASAC sees immediate need for action
https://european-biotechnology.net/wp-content/uploads/2025/09/MRM-Health_287620039_HOUCde1qR0jiIIPYUSaejdsrkISIIa3P.jpg
750
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-09-04 08:14:072025-09-04 08:14:07Microbiome play MRM Health NV raises €55m in Series B
https://european-biotechnology.net/wp-content/uploads/2025/09/Lewy_Body_alphaSynuclein-e1756879718600.jpg
355
631
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-09-03 09:06:552025-09-04 10:32:03Novartis invests US$200min lacklustre Parkinson’s target
https://european-biotechnology.net/wp-content/uploads/2025/09/Cytokinetics_Headquarters-e1756871185507-1030x580-1.jpg
580
1030
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-09-03 03:48:112025-09-03 03:48:11Cytokinetics’ Aficamten with breakthrough Phase III results
https://european-biotechnology.net/wp-content/uploads/2025/09/Polpharma-Biologics-HQ-in-Gdansk-1-2-1-e1756822843167.jpg
451
800
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-09-02 14:29:112025-09-02 14:29:11Polpharma Biologics secures distribution of upcoming biosimilars
https://european-biotechnology.net/wp-content/uploads/2025/09/Genetech_320984427_b8PYYp7YaXx5WBi6WwRXFIg8OupDixUA-e1756802020857.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-09-02 08:37:032025-09-02 08:37:03Genentech inks US$400m IBD deal with OMass Therapeutics
https://european-biotechnology.net/wp-content/uploads/2025/09/Sanofi_1090062434_e0WmVrZU84Vl6P9grrRF5Cmpr0yUupgT-e1756740428940.jpg
563
1000
Thomas Gabrielczyk
/wp-content/uploads/2019/12/ebn-1-300x135.png
Thomas Gabrielczyk2025-09-01 15:27:512025-09-01 15:27:51Sanofi receives US approval for oral ITP blockbuster
Scroll to top
